TTM
$14.31B
YoY change
+37.4%
5Y CAGR
+21.6%
Peak year (2025)
$13.74B
Cumulative operating income
$182.98B
Operating Income history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $13.74B
Operating Income growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: +37.4%
Operating Income history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $13.74B | +37.4% | +$3.74B | ||
| 2024 | $10.00B | +22.1% | +$1.81B | ||
| 2023 | $8.19B | +118.1% | +$4.44B | ||
| 2022 | $3.76B | +255.8% | +$2.70B | ||
| 2021 | $1.06B | -79.5% | −$4.11B | ||
| 2020 | $5.16B | +76.5% | +$2.24B | ||
| 2019 | $2.92B | -13.7% | −$463.00M | ||
| 2018 | $3.39B | -7.9% | −$290.00M | ||
| 2017 | $3.68B | -25.0% | −$1.23B | ||
| 2016 | $4.90B | +19.2% | +$788.00M | ||
| 2015 | $4.11B | +92.5% | +$1.98B | ||
| 2014 | $2.14B | -42.4% | −$1.57B | ||
| 2013 | $3.71B | -54.4% | −$4.44B | ||
| 2012 | $8.15B | -36.3% | −$4.65B | ||
| 2011 | $12.79B | +11.3% | +$1.30B | ||
| 2010 | $11.49B | -0.4% | −$49.00M | ||
| 2009 | $11.54B | +26.2% | +$2.40B | ||
| 2008 | $9.14B | +13.0% | +$1.05B | ||
| 2007 | $8.09B | -1.5% | −$122.00M | ||
| 2006 | $8.22B | +26.4% | +$1.71B | ||
| 2005 | $6.50B | +43.0% | +$1.96B | ||
| 2004 | $4.55B | +13.5% | +$540.00M | ||
| 2003 | $4.01B | +0.0% | +$1.00M | ||
| 2002 | $4.01B | -3.6% | −$150.00M | ||
| 2001 | $4.16B | +13.4% | +$490.69M | ||
| 2000 | $3.67B | +6.9% | +$235.31M | ||
| 1999 | $3.43B | +41.3% | +$1.00B | ||
| 1998 | $2.43B | +35.6% | +$636.68M | ||
| 1997 | $1.79B | +0.2% | +$4.18M | ||
| 1996 | $1.79B | +39.4% | +$505.16M | ||
| 1995 | $1.28B | +24.3% | +$250.70M | ||
| 1994 | $1.03B | -1.1% | −$11.08M | ||
| 1993 | $1.04B | +142.6% | +$612.13M | ||
| 1992 | $429.22M | -66.4% | −$846.93M | ||
| 1991 | $1.28B | +10.3% | +$118.79M | ||
| 1990 | $1.16B | — | — |
- 2025$13.74B+37.4%
- 2024$10.00B+22.1%
- 2023$8.19B+118.1%
- 2022$3.76B+255.8%
- 2021$1.06B-79.5%
- 2020$5.16B+76.5%
- 2019$2.92B-13.7%
- 2018$3.39B-7.9%
- 2017$3.68B-25.0%
- 2016$4.90B+19.2%
- 2015$4.11B+92.5%
- 2014$2.14B-42.4%
- 2013$3.71B-54.4%
- 2012$8.15B-36.3%
- 2011$12.79B+11.3%
- 2010$11.49B-0.4%
- 2009$11.54B+26.2%
- 2008$9.14B+13.0%
- 2007$8.09B-1.5%
- 2006$8.22B+26.4%
- 2005$6.50B+43.0%
- 2004$4.55B+13.5%
- 2003$4.01B+0.0%
- 2002$4.01B-3.6%
- 2001$4.16B+13.4%
- 2000$3.67B+6.9%
- 1999$3.43B+41.3%
- 1998$2.43B+35.6%
- 1997$1.79B+0.2%
- 1996$1.79B+39.4%
- 1995$1.28B+24.3%
- 1994$1.03B-1.1%
- 1993$1.04B+142.6%
- 1992$429.22M-66.4%
- 1991$1.28B+10.3%
- 1990$1.16B—
Operating Income values are taken from AstraZeneca's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's current operating income (TTM) is $14.31B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of AstraZeneca (AZN) operating income is $13.74B – surged 37.4% year-over-year.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca operating income compounded at +21.6% per year, sustaining 4 straight years of year-over-year growth.
2025 marks the peak operating income at $13.74B, with the historical low of $429.22M recorded in 1992.
AstraZeneca Operating Income by Year
AstraZeneca Operating Income 2025: $13.74B
2025's operating income for AstraZeneca came in at $13.74B, surged 37.4% from 2024. This figure represents the highest annual value in the available history.
AstraZeneca Operating Income 2024: $10.00B
AstraZeneca posted operating income of $10.00B in 2024, grew 22.1% from 2023.
AstraZeneca Operating Income 2023: $8.19B
In 2023, AstraZeneca reported operating income of $8.19B, surged 118.1% from 2022.
AstraZeneca Operating Income 2022: $3.76B
AstraZeneca operating income in 2022 was $3.76B, surged 255.8% from 2021.
AstraZeneca Operating Income 2021: $1.06B
AstraZeneca operating income in 2021 was $1.06B.
See more financial history for AstraZeneca (AZN).
Sector peers by Operating Income
Healthcare peers of AstraZeneca (AZN), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $10.68B | |
| $8.11B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $10.68B
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation